TY - JOUR
T1 - Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy
T2 - Glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients
AU - Masuda, H.
AU - Sakamoto, M.
AU - Irie, J.
AU - Kitaoka, A.
AU - Shiono, K.
AU - Inoue, G.
AU - Atsuda, K.
AU - Yamada, Satoru
PY - 2008
Y1 - 2008
N2 - Objective: The aim of this study was to evaluate twice-daily injections of biphasic insulin lispro vs. basal-bolus (BB) therapy with regard to quality-of-life (QOL) and glycaemic control in insulin-naïve type 2 diabetic patients. Methods: Twenty-eight patients with type 2 diabetes were randomized to receive either twice-daily 50/50 premixed insulin lispro (Mix50 group) or BB (NPH insulin at bedtime and preprandial insulin lispro) therapy (BB group) for 12 weeks. Glycated haemoglobin (HbA1C), 1,5-anhydroglucitol (1,5-AG), blood plasma glucose level, body mass index (BMI), daily total insulin dosage and insulin therapy-related QOL (ITR-QOL) were studied. Results: ITR-QOL was significantly better in the Mix50 than in the BB group (103.1 ± 9.8 vs. 90.6 ± 19.4; p < 0.05). HbA1c improved in both groups (from 11.1 ± 2.1 to 6.9 ± 1.0% with Mix50 vs. from 11.0 ± 2.3 to 6.6 ± 0.8% with BB therapy). Conclusion: These results might suggest that twice-daily injections of premixed rapid-acting insulin analogue therapy could achieve good glycaemic control and better QOL compared with BB therapy in insulin-naïve type 2 diabetes.
AB - Objective: The aim of this study was to evaluate twice-daily injections of biphasic insulin lispro vs. basal-bolus (BB) therapy with regard to quality-of-life (QOL) and glycaemic control in insulin-naïve type 2 diabetic patients. Methods: Twenty-eight patients with type 2 diabetes were randomized to receive either twice-daily 50/50 premixed insulin lispro (Mix50 group) or BB (NPH insulin at bedtime and preprandial insulin lispro) therapy (BB group) for 12 weeks. Glycated haemoglobin (HbA1C), 1,5-anhydroglucitol (1,5-AG), blood plasma glucose level, body mass index (BMI), daily total insulin dosage and insulin therapy-related QOL (ITR-QOL) were studied. Results: ITR-QOL was significantly better in the Mix50 than in the BB group (103.1 ± 9.8 vs. 90.6 ± 19.4; p < 0.05). HbA1c improved in both groups (from 11.1 ± 2.1 to 6.9 ± 1.0% with Mix50 vs. from 11.0 ± 2.3 to 6.6 ± 0.8% with BB therapy). Conclusion: These results might suggest that twice-daily injections of premixed rapid-acting insulin analogue therapy could achieve good glycaemic control and better QOL compared with BB therapy in insulin-naïve type 2 diabetes.
KW - Insulin lispro
KW - Insulin therapy
KW - Quality-of-life
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=55449093897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55449093897&partnerID=8YFLogxK
U2 - 10.1111/j.1463-1326.2008.00897.x
DO - 10.1111/j.1463-1326.2008.00897.x
M3 - Article
C2 - 18494811
AN - SCOPUS:55449093897
SN - 1462-8902
VL - 10
SP - 1261
EP - 1265
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 12
ER -
